Do more for patients with visual acuity loss due to intermediate AMD or Geographic Atrophy.

The i-SIGHT2 study provides eye care professionals with a potential therapy option for patients with visual acuity loss due to intermediate AMD or non-subfoveal GA secondary to AMD.

Refer a patient

i-Lumen® AMD therapy delivers pulsed, microcurrent electrical stimulation to the retina to repolarize the RPE, the source of dysfunction that leads to progression of AMD.

The objective of the i‑SIGHT2 research study is to evaluate the safety and effectiveness of the i‑Lumen AMD therapy, and determine whether the technology can improve visual acuity or slow the progression of intermediate AMD or non-subfoveal GA secondary to AMD.

Study participants must meet the following criteria:

60 years of age or older

Intermediate AMD or Geographic Atrophy secondary to AMD in one or both eyes

At least one large central drusen

Best-corrected Visual Acuity (BCVA) no better than 20/40 and no worse than 20/200

Do more for patients with visual acuity loss due to intermediate AMD or Geographic Atrophy.

i-Lumen® AMD therapy delivers pulsed, microcurrent electrical stimulation to the retina to repolarize the RPE, the source of dysfunction that leads to progression of AMD.

Exclusion Criteria

Contact us to learn more or refer a patient

Contact us to learn more about the study or refer a patient